Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$1.24 - $2.19 $446,401 - $788,402
360,001 New
360,001 $720,000
Q1 2022

May 16, 2022

SELL
$1.72 - $2.82 $848,873 - $1.39 Million
-493,531 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$2.66 - $7.45 $1.31 Million - $3.68 Million
493,531 New
493,531 $1.31 Million

Others Institutions Holding CNTX

About Context Therapeutics Inc.


  • Ticker CNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,966,100
  • Market Cap $16.3M
  • Description
  • Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therape...
More about CNTX
Track This Portfolio

Track Altium Capital Management LP Portfolio

Follow Altium Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Altium Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Altium Capital Management LP with notifications on news.